Leading the Next Generation of Delicious, Natural and Nutritious Food: Upfield Renamed as Flora Food Group
Upfield Group B.V., global branded food champion, announces today that it has changed its name to Flora Food Group B.V. The name change is a substantial step in the company's evolution and follows a performance-driven transformation on multiple levels across the entire company.
The new name reflects Flora Food Group’s evolved purpose of delivering the next generation of delicious, natural, and nutritious food that is more affordable and more sustainable than its dairy equivalents. Capitalizing on four global megatrends (population growth, demand for dairy-alternative solutions, animal welfare concerns, and environmental regulations), Flora Food Group leads the change with products that address these trends across four growing categories - butter and spreads, creams, liquids, and cheese - offering consumers a compelling choice.
Leveraging its 150+ years of heritage and in-depth R&D expertise, Flora Food Group will seek to drive further conversion in butter, creams, liquids, and cheese, offering exciting growth opportunities for its iconic brands, local brands and professional business.
David Haines, Group CEO of Flora Food Group, commented: "The name change to Flora Food Group is an exciting and logical step in the large-scale transformation we have delivered. We have fully reinvented our company. The new name better reflects who we are, with Flora being one of our longest-standing and most popular brands loved by millions of families and professionals around the world. This name also evokes the company's rich heritage and broad portfolio. It conveys our great passion to make delicious, natural, and nutritious food, helping to nourish hundreds of millions of families every day.”
The name change will take effect immediately at the Dutch corporate level, with a phased approach across Flora Food Group’s global markets in the months ahead. Visit www.florafoodgroup.com for more information.
About Flora Food Group:
Global branded food champion Flora Food Group offers the next generation of delicious, natural, nutritious food. Our products are more affordable and more sustainable than their dairy equivalents. We offer consumers a compelling choice in four growing categories: butters and spreads, creams, liquids, and cheeses. We hold leadership positions in many of the 100 countries we operate in, with iconic brands including Flora, Becel+ProActiv, BlueBand, Country Crock, I Can’t Believe It’s Not Butter, Rama, and Violife, together with our local brands and Professional business. We have 150+ years of heritage, deep R&D expertise and a relentless commitment to delivering delicious, nutritious food. We own 14 manufacturing sites across five continents. Flora Food Group is headquartered in Amsterdam (Netherlands) and employs ~4,800 people; the company reported net sales of EUR 3.3 billion in 2023, making it the global leader in plant-based food.
This press release may contain forward-looking statements with respect to Flora Food Group’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of Flora Food Group and information currently available to the company. Flora Food Group cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Flora Food Group has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917264963/en/
Contacts
Flora Food Group Media Relations
medialine@florafg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom